Bristol Myers Squibb’s new product lineup delivered a 17% increase in sales during the first nine months of 2025, driven largely by oncology and immunology franchises. Key growth drivers included the blood cancer therapy Camzyos and the rheumatoid arthritis treatment Sotyktu, which collectively contributed over $3 billion in additional revenue year-over-year. Management projects that these growth assets will sustain double-digit top-line gains through 2026 as launches in Europe and Asia ramp up and label expansions broaden patient access.

Offsetting much of the growth portfolio’s momentum, legacy product sales declined by 16% in the same period, reflecting intensifying generic competition for the long-standing cholesterol drug Repatha and the patent expiration on the hepatitis C franchise. The company forecasts an ongoing erosion rate of around 10% for its mature assets through the next two fiscal years, necessitating further pipeline success if overall revenue targets are to be met.

Recent data from Zacks.com indicates a surge in user activity around Bristol Myers Squibb, with search interest increasing by 25% over the past month. Several equity research firms have revised their outlooks, citing a potential dividend raise following the stabilization of free cash flow in 2025. Consensus analyst earnings estimates for 2026 currently sit 8% above last year’s consensus, reflecting growing confidence in the new drug portfolio and cost-optimization initiatives.